Roche enters the race for liver disease drugs, acquires US biotech Jecure
With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors. Swiss drugmaker Roche is buying Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases. According to a definitive agreement, Jecure will be acquired by Genentech, which is a member of the Roche Group. […]
Roche enters the race for liver disease drugs, acquires US biotech Jecure Read More »












